A3384
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bile Acid Malabsorption
Conditions
Bile Acid Malabsorption
Trial Timeline
Mar 1, 2014 → Dec 1, 2014
NCT ID
NCT02078856About A3384
A3384 is a phase 2 stage product being developed by Ipsen for Bile Acid Malabsorption. The current trial status is completed. This product is registered under clinical trial identifier NCT02078856. Target conditions include Bile Acid Malabsorption.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02078856 | Phase 2 | Completed |
Competing Products
13 competing products in Bile Acid Malabsorption
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 77 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 52 |
| Gemcitabine + Cisplatin + Durvalumab | AstraZeneca | Phase 2 | 52 |
| IL-10 | Merck | Phase 2 | 52 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 52 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 49 |
| Cabozantinib | Exelixis | Phase 2 | 49 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| Cholbam | Mirum Pharmaceuticals | Pre-clinical | 20 |
| Cholic Acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| GM-CT-01 + 5-Fluorouracil | Galectin Therapeutics | Phase 2 | 44 |